within Pharmacolibrary.Drugs.V_Various.V01A_Allergens.V01AA10_Flowers;
model Flowers 
   extends Pharmacolibrary.Drugs.ATC.V.V01AA10;

  annotation(Documentation(
    info ="<html><body><p>The drug with the name 'flowers' and ATC code V01AA10 does not correspond to any known or approved pharmacological agent. ATC code V01AA10 is officially allocated to test allergens for inhalation, particularly pollen allergens (flower pollen products) used for allergy testing, not a conventional medicinal drug. These agents are generally used for allergy diagnostic purposes, not actual treatment, and are not administered for systemic pharmacological action. There is no modern drug named 'flowers' used or approved today for therapy.</p><h4>Pharmacokinetics</h4><p>No pharmacokinetic data available, as V01AA10 products (pollen allergens for inhalant allergy testing) are not intended to be systemic drugs. No publications reporting pharmacokinetic parameters could be found.</p><h4>References</h4><ol><li><p>Manca, A, et al., &amp; D&#x27;Avolio, A (2024). Cannabinoid levels description in a cohort of patients with chronic and neuropathic pain treated with Cannabis decoction: A possible role of TDM. <i>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</i> 175 116686–None. DOI:<a href=&quot;https://doi.org/10.1016/j.biopha.2024.116686&quot;>10.1016/j.biopha.2024.116686</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38713939/&quot;>https://pubmed.ncbi.nlm.nih.gov/38713939</a></p></li><li><p>Behzad, D, et al., &amp; Di Ciano, P (2025). Effects of different methods of cannabis use on cognition and blood THC: A systematic review. <i>Progress in neuro-psychopharmacology &amp; biological psychiatry</i> 139 111399–None. DOI:<a href=&quot;https://doi.org/10.1016/j.pnpbp.2025.111399&quot;>10.1016/j.pnpbp.2025.111399</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/40368229/&quot;>https://pubmed.ncbi.nlm.nih.gov/40368229</a></p></li><li><p>Henthorn, TK, et al., &amp; Kosnett, M (2024). Dose Estimation Utility in a Population Pharmacokinetic Analysis of Inhaled Δ9-Tetrahydrocannabinol Cannabis Market Products in Occasional and Daily Users. <i>Therapeutic drug monitoring</i> 46(5) 672–680. DOI:<a href=&quot;https://doi.org/10.1097/FTD.0000000000001224&quot;>10.1097/FTD.0000000000001224</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39235358/&quot;>https://pubmed.ncbi.nlm.nih.gov/39235358</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Flowers;
